Next Article in Journal
Analysis of Liver-Directed Therapies in U.S. Cancer Patients
Previous Article in Journal
Impact of Country-Specific EQ-5D-3L Tariffs on the Economic Value of Systemic Therapies Used in the Treatment of Metastatic Pancreatic Cancer
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Pilot Study Using the Chinese Herbal Paste Liu-He-Dan to Manage Radiodermatitis Associated with Breast Cancer Radiotherapy

1
Department of Chemotherapy, Sichuan Cancer Hospital, Chengdu, Sichuan, China
2
Department of Gastroenterology, The First Affiliated Hospital, Chengdu Medical College, Chengdu, Sichuan, China
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(6), 453-456; https://doi.org/10.3747/co.22.2725
Submission received: 4 September 2015 / Revised: 10 October 2015 / Accepted: 8 November 2015 / Published: 1 December 2015

Abstract

Background: During radiotherapy for breast cancer, patients are greatly affected by pain, infection, and delayed healing of wounds caused by radiodermatitis. In the present study, we aimed to determine the efficacy of Liu-He-Dan in treating radiodermatitis. Methods: In 26 breast cancer patients who experienced moist decrustation while receiving radiotherapy, 5 g Liu-He-Dan was applied externally once daily after the wound surface had been cleaned and dried. The healing time was recorded, and a Kaplan–Meier survival curve was applied to analyze the treatment course. Meanwhile, a pain assessment using the Numeric Rating Scale (nrs) recorded the pain level experienced by patients after application of the Liu-He-Dan. Results: After application of Liu-He-Dan, the average healing time for the surface of the moist decrustation wounds was 14.17 ± 2.03 days (range: 5–22 days). Inflammatory seepage decreased significantly and exudation almost disappeared in 3 days. The pain trend line indicated that the average nrs score declined with treatment in all patients. The average nrs scores at days 1, 4, and 7 were 6.13, 3.62, and 2.58 respectively. After 3 days of treatment, pain was remarkably alleviated in 80.76% of patients. After treatment for 1 week, the pain remission rate was 96.15%, without any obvious adverse reactions. Conclusions: Liu-He-Dan was efficacious in treating radiation skin injury with little toxicity and few side effects; the economic efficiency of the treatment was also favourable. The Liu-He-Dan was generally well tolerated by patients. In future, randomized control trials will be established for further observation of the value of Liu-He-Dan in treating radiodermatitis in breast cancer.
Keywords: Liu-He-Dan; radiodermatitis; breast cancer Liu-He-Dan; radiodermatitis; breast cancer

Share and Cite

MDPI and ACS Style

Zhou, J.; Fang, L.; Xie, H.; Yao, W.X.; Zhou, X.; Xiong, Z.J. A Pilot Study Using the Chinese Herbal Paste Liu-He-Dan to Manage Radiodermatitis Associated with Breast Cancer Radiotherapy. Curr. Oncol. 2015, 22, 453-456. https://doi.org/10.3747/co.22.2725

AMA Style

Zhou J, Fang L, Xie H, Yao WX, Zhou X, Xiong ZJ. A Pilot Study Using the Chinese Herbal Paste Liu-He-Dan to Manage Radiodermatitis Associated with Breast Cancer Radiotherapy. Current Oncology. 2015; 22(6):453-456. https://doi.org/10.3747/co.22.2725

Chicago/Turabian Style

Zhou, J., L. Fang, H. Xie, W.X. Yao, X. Zhou, and Z.J. Xiong. 2015. "A Pilot Study Using the Chinese Herbal Paste Liu-He-Dan to Manage Radiodermatitis Associated with Breast Cancer Radiotherapy" Current Oncology 22, no. 6: 453-456. https://doi.org/10.3747/co.22.2725

Article Metrics

Back to TopTop